RBC Capital Sticks to Its Hold Rating for Wave Life Sciences (WVE)

RBC Capital analyst Luca Issi maintained a Hold rating on Wave Life Sciences (WVE – Research Report) yesterday and set a price target of $5.00. The company’s shares closed yesterday at $5.76.

According to TipRanks, Issi is an analyst with an average return of -22.8% and a 19.80% success rate. Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Moderna, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Wave Life Sciences with a $13.20 average price target.

Based on Wave Life Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $29.06 million and a GAAP net loss of $16.26 million. In comparison, last year the company earned a revenue of $1.24 million and had a GAAP net loss of $43.71 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Wave Life Sciences (WVE) Company Description:

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.